Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INS1033 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1: Single Ascending Dose (SAD) | EXPERIMENTAL | Participants will receive single ascending dose (SAD) of INS1033 or a matching placebo orally under fasted conditions on Day 1. |
| Part 2: Multiple Ascending Dose (MAD) | EXPERIMENTAL | Participants will receive multiple ascending dose (MAD) of INS1033 or a matching placebo orally under fasted conditions for up to 14 days. |
| Name | Type | Description |
|---|---|---|
| INS1033 | DRUG | Oral solution |
| Placebo | DRUG | Oral solution |
Inclusion Criteria: * Healthy status as defined by the absence of evidence of any clinically significant, in the opinion of the Investigator, active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead electrocardiogram...
INS1033 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development to assess its safety, tolerability, and pharmacokinetics. The drug is not approved for any condition and is being evaluated in a clinical trial setting.
INS1033 is being developed by Insmed Incorporated, a biopharmaceutical company traded on NASDAQ under the ticker symbol INSM. The company is conducting a Phase 1 study to evaluate the drug's safety, tolerability, and pharmacokinetics in healthy participants.
INS1033 is in Phase 1 clinical development. It is an investigational drug being studied in a single Phase 1 trial that has not yet begun recruiting participants. The drug is not FDA approved and remains in early-stage clinical testing.
INS1033 is being studied in one clinical trial, identified as NCT07765706. This Phase 1 study is designed to assess the safety, tolerability, and pharmacokinetics of INS1033 in healthy participants. The trial is not yet recruiting and has a planned enrollment of 116 participants.
INS1033 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The ongoing study is designed to evaluate its safety, tolerability, and pharmacokinetics in healthy volunteers, and the drug has not yet demonstrated efficacy or received regulatory approval.